2015 Fiscal Year Final Research Report
Assessment of T-cell based immunotherapy targeting EGFR with immune-molecular targeted combination therapy for treatment of reflactory cancer.
| Project/Area Number |
25460430
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Asahikawa Medical College |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | 腫瘍免疫 |
|---|
| Outline of Final Research Achievements |
We evaluated the capacity of predicted CD4 T-cell peptide epitopes from HER family to induce anti-tumor immune responses. Among several predicted peptide epitopes, EGFR875-889 elicited CD4 T cell responses that were restricted by several HLA-DR alleles, indicating that the peptide functions as a promiscuous T cell epitope. The CD4 T cells were capable of directly recognized and killed HNSCC or lymphoma cells expressing antigens. Finally, we examined whether an EGFR tyrosine kinase inhibitor would affect CD4 T cell tumor reactivity. Treatment of tumor cells with the EGFR inhibitors enhanced tumor recognition by EGFR875-889 reactive T cells presumably due to the up-regulation of HLA-DR expression in the tumor cells. The results demonstrate the utility of EGFR inhibitors as immune modulators. These observations may facilitate the translation of T-cell based immunotherapy into the clinic for the treatment of maligancies and rational explanation for immune-targeted combination therapy.
|
| Free Research Field |
病理学
|
